Clinical trials: Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia
Endometrial Neoplasms, Endometrial Cancer
Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia
This is a single-center, randomized, open-label, controlled clinical trial evaluating whether adding orlistat to standard progestin therapy can improve treatment response in patients receiving fertility-sparing treatment for…
- Conditions
- Endometrial Neoplasms, Endometrial Cancer, Atypical Endometrial Hyperplasia, Progestin Resistance
- Trial name
- PKUPH-ORLPP-EC (NCT07714070)
- Testing
- Orlistat, Progestin
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Peking University People's Hospital
Endometrial Cancer, Atypical Endometrial Hyperplasia
Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC
Primary end points: This clinical trial is aimed to analyze the effectiveness of Levonorgestrel-Releasing Intrauterine System (LNG-IUS, Mirena®) in the fertility-sparing treatment of atypical endometrial hyperplasia and early…
- Trial name
- NCT03463252
- Testing
- Progesterone, Mirena®, GnRH agonist
- Where
- China
- Volunteers
- 224 people
- Sponsor
- West China Second University Hospital
Endometrial Carcinoma Stage I, Atypical Endometrial Hyperplasia
Patient-derived Tumor-like Cell Clusters Predict Progesterone Sensitivity in Patients With Early Endometrial Cancer
To construct a prediction model of progesterone sensitivity in patients with endometrial cancer treated with fertility preservation
- Trial name
- NCT05647109
- Testing
- No intervention
- Where
- China
- Volunteers
- 244 people
- Sponsor
- Peking University People's Hospital
Endometrial Hyperplasia
Efficacy of LNG-IUS for Treatment of Non-atypical Endometrial Hyperplasia in Perimenopausal Women
The purpose of this study is to compare the efficacy of the Levonorgestrel releasing Intrauterine System (Mirena) and Norethisterone Acetate for treatment of non-atypical endometrial hyperplasia in perimenopausal women.
- Trial name
- NCT01499602
- Testing
- LNG-IUS; Mirena; Bayer Schering Pharma Oy, Finland, Norethisterone Acetate tablets
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Mansoura University
Endometrial Cancer, Cervical Cancer
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human…
- Conditions
- Endometrial Cancer, Cervical Cancer, Atypical Endometrial Hyperplasia, Cervical Dysplasia
- Trial name
- ECHO (NCT05051722)
- Testing
- Vaginal Fluid Collection, Blood Collection
- Where
- 25 sites in United States
- Volunteers
- 3,110 people
- Sponsor
- Mayo Clinic
Atypical Endometrial Hyperplasia
Metformin Plus Megestrol Acetate As a Fertility-sparing Treatment in Patients with Atypical Endometrial Hyperplasia
To verify whether metformin could improve the effect of progestin as fertility-sparing treatment in patients with atypical endometrial hyperplasia(AEH).
- Trial name
- NCT04607252
- Testing
- Metformin plus Megestrol acetate, Megestrol Acetate
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Fudan University
Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia
Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer
The goal of this clinical trial is to learn if a combination treatment of a hormonal intrauterine device (LNG-IUD), semaglutide, and a structured weight loss program can treat endometrial atypical hyperplasia or grade 1…
- Conditions
- Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Cancer Stage I, Endometrial Cancer
- Trial name
- SWIFT (NCT07820358)
- Testing
- Semaglutide (Wegovy) weekly injection, LNG-IUD (Progestin), Structured Weight Loss Program
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- The Methodist Hospital Research Institute
Endometrial Cancer, Hereditary Non-polyposis Colon Cancer (hmsh2, hmlh1, hpms1, hpms2)
Intrauterine Levonorgestrel and Observation or Observation Alone in Preventing Atypical Endometrial Hyperplasia and Endometrial Cancer in Women With Hereditary Non-Polyposis Colorectal Cancer or Lynch Syndrome
RATIONALE: The use of intrauterine levonorgestrel may prevent atypical endometrial hyperplasia and endometrial cancer in women with hereditary non-polyposis colorectal cancer or Lynch syndrome.
- Trial name
- NCT00566644
- Testing
- levonorgestrel-releasing intrauterine system, questionnaire administration, observation
- Where
- 20 sites in United Kingdom
- Volunteers
- 600 people
- Sponsor
- St George's, University of London
Endometrial Cancer, Atypical Endometrial Hyperplasia
Liquid Biopsy-Based Early Screening for Endometrial Cancer in Regional Chinese Populations
Endometrial cancer is one of the most common gynecological malignancies, and its incidence is rising. Currently, there is a lack of highly effective and non-invasive screening methods.
- Trial name
- NCT07892755
- Where
- China
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- Guizhou Provincial People's Hospital
Endometrial Hyperplasia, Grade 1 Endometrial Cancer
Uterine Preservation Via Lifestyle Transformation
Up to 60% of endometrial cancer cases are attributed to obesity, in part because obesity promotes development of atypical endometrial hyperplasia (AEH), and up to 40% of women with AEH go on to develop endometrial cancer.
- Trial name
- NCT05903131
- Testing
- Telemedicine behavioral weight intervention, Progestin, Enhanced usual care
- Where
- 3 sites in United States
- Volunteers
- 96 people
- Sponsor
- Washington University School of Medicine
Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia
Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer
This pilot phase IIa trial studies how well exemestane works in treating patients with complex atypical hyperplasia of the endometrium/endometrial intraepithelial neoplasia or low grade endometrial cancer.
- Conditions
- Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Carcinoma, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
- Trial name
- NCT03300557
- Testing
- Exemestane, Laboratory Biomarker Analysis, Pharmacokinetic Study
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Carcinoma
Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer
This phase II trial studies the effect of megestrol acetate alone or in combination with metformin in preventing the progression of uterine pre-cancer (endometrial intraepithelial neoplasia) to endometrial cancer.
- Trial name
- NCT04576104
- Testing
- Biopsy Procedure, Extended Release Metformin Hydrochloride, Megestrol Acetate
- Where
- 8 sites in United States
- Volunteers
- 51 people
- Sponsor
- Northwestern University
Atypical Endometrial Hyperplasia, Fertility Issues
Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia
To investigate the efficacy of weight management plus levonorgestrel intrauterine system (LNG-IUS) or megestrol acetate (MA) in obese patients with endometrial atypical hyperplasia (EAH) asking for conservative therapy.
- Conditions
- Atypical Endometrial Hyperplasia, Fertility Issues, Overweight and Obesity
- Trial name
- NCT05316493
- Testing
- Intensive Lifestyle Intervention (ILI), Megestrol Acetate 160 MG Oral Tablet, Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Xiaojun Chen
Complex Endometrial Hyperplasia With Atypia, Stage IA Uterine Corpus Cancer
Weight Loss Referral for Healthier Survivorship in Obese Stage I-II Endometrial Cancer Survivors or Atypical Hyperplasia
This pilot clinical trial studies whether obese stage I-II endometrial cancer survivors or patients with atypical hyperplasia (abnormal cells in the lining of the uterus) would go see a weight loss specialist if it was…
- Conditions
- Complex Endometrial Hyperplasia With Atypia, Stage IA Uterine Corpus Cancer, Stage IB Uterine Corpus Cancer, Stage II Uterine Corpus Cancer
- Trial name
- NCT02342730
- Testing
- Weight Loss Specialist, Quality-of-Life Assessment, Medical Chart Review
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- Case Comprehensive Cancer Center
Atypical Endometrial Hyperplasia
Megestrol Acetate Plus LNG-IUS in Young Women With Endometrial Atypical Hyperplasia
To see if megestrol acetate plus Levonorgestrel-releasing intrauterine system (LNG-IUS) will not be inferior to returning the endometrial tissue to a normal state than megestrol acetate or LNG-IUS alone in patients with…
- Trial name
- NCT03241888
- Testing
- Megestrol Acetate, Levonorgestrel-releasing Intrauterine System(LNG-IUS)
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Fudan University
Atypical Endometrial Hyperplasia, Stage I Uterine Corpus Cancer AJCC v7
Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer
This phase II trial studies how well levonorgestrel-releasing intrauterine system works in treating patients with complex atypical hyperplasia or grade I endometrial cancer.
- Conditions
- Atypical Endometrial Hyperplasia, Stage I Uterine Corpus Cancer AJCC v7, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7
- Trial name
- NCT00788671
- Testing
- Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System, Quality-of-Life Assessment
- Where
- 7 sites in United States
- Volunteers
- 69 people
- Sponsor
- M.D. Anderson Cancer Center
Atypical Endometrial Hyperplasia, Endometrial Carcinoma
Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
The purpose of this trial is to study the efficacy, toxicity, and tolerability of a standard hormonal regimen of Megestrol Acetate (Megace) in the treatment of Atypical Endometrial Hyperplasia or well to moderately differentiated…
- Trial name
- NCT00483327
- Testing
- Megestrol Acetate
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- NYU Langone Health
Abnormal Uterine Bleeding (AUB), Endometrial Cancer
Endometrial Cancer Vaginal Fluid Specimen Collection Study
This is a multicenter, prospective, specimen collection study for development and evaluation of tests used to detect endometrial cancer, other cancers, or their causes.
- Conditions
- Abnormal Uterine Bleeding (AUB), Endometrial Cancer, Atypical Endometrial Hyperplasia, Endometrial Hyperplasia With Atypia
- Trial name
- ENVISION (NCT07544680)
- Where
- 5 sites in United States
- Volunteers
- 4,200 people
- Sponsor
- Exact Sciences Corporation
Atypical Endometrial Hyperplasia, Endometrial Adenocarcinoma
Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer
This randomized phase II trial studies how well megestrol acetate or levonorgestrel-releasing intrauterine system works in treating patients with atypical endometrial hyperplasia or endometrial cancer.
- Conditions
- Atypical Endometrial Hyperplasia, Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Stage IA Endometrial Carcinoma
- Trial name
- NCT01943058
- Testing
- megestrol acetate, levonorgestrel-releasing intrauterine system, laboratory biomarker analysis
- Sponsor
- University of Southern California
Endometrial Neoplasms, Atypical Endometrial Hyperplasia
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
To investigate the efficacy of GnRHa plus letrozole in obese progestin-insensitive EEC patients.
- Conditions
- Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance, Obesity
- Trial name
- NCT06379113
- Testing
- GnRH antagonist, Letrozole 2.5mg
- Where
- 2 sites in China
- Volunteers
- 29 people
- Sponsor
- Xiaojun Chen